Pacira price target raised to $24 from $17 at Barclays

Barclays raised the firm’s price target on Pacira (PCRX) to $24 from $17 and keeps an Equal Weight rating on the shares after the company’s FY25 revenue guidance was in-line with the Street at the mid-point of $745M. The firm views the company’s acquisition of remaining 81% equity stake in GQ Bio positively as it eliminates future milestones and brings with it a novel platform and preclinical assets, the analyst tells investors.